IFM Therapeutics Appoints Leading Oncology, Immunology, and Chemistry Experts to Founding Scientific Advisory Board
IFM Therapeutics today announced the appointment of seven renowned scientists to its scientific advisory board. The company, which recently closed a $27 million Series A financing, is developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of cancer and inflammatory diseases.
“We are delighted to have such an accomplished and distinguished group of scientists join our team,” said Shomir Ghosh, Chief Scientific Officer at IFM. “Their expertise and guidance will be instrumental as we advance our existing preclinical programs and expand our pipeline of novel immunomodulators.”
Members of the IFM scientific advisory board are:
- Diane Mathis (Chair), PhD, Professor of Microbiology and Immunobiology, Harvard Medical School; Member, National Academy of Sciences
- Erick M. Carreira, PhD, Head, Laboratory of Organic Chemistry, ETH Zürich
- Douglas T. Fearon, MD FRS FMedSci, Professor, Cold Spring Harbor Laboratory; Walter B. Wriston Professor of Pancreatic Cancer Research, Weill Cornell Medicine; Emeritus Sheila Joan Smith Professor of Immunology, University of Cambridge; Member, National Academy of Sciences
- Nir Hacohen, PhD, Director, Center for Cancer Immunology, Massachusetts General Hospital; Harvard Medical School; Broad Institute
- William L. Jorgensen, PhD, Sterling Professor of Chemistry, Yale University; Member, National Academy of Sciences
- Jonathan C. Kagan, PhD, Associate Professor of Pediatrics, Harvard Medical School; Shwachman Chair in Gastroenterology, Staff Scientist, Boston Children's Hospital
- Alexander Rudensky, PhD, Chairman, Immunology Program, Sloan-Kettering Institute; Investigator, Howard Hughes Medical Institute; Director, Ludwig Center for Cancer Immunotherapy; Tri-Institutional Professor at MSKCC, The Rockefeller University and Cornell University; Member, National Academy of Sciences
Diane Mathis, chair of the SAB, commented, “IFM’s novel approaches to target the innate immune system hold great promise. The SAB is uniformly impressed with the rigor and progress of the company and we look forward to helping IFM realize the potential of this exciting area of biology.”
“In addition to the founding scientific team, our SAB members add significant depth in several areas that are key to the company’s mission including chemistry, cancer biology, immunology, and bioinformatics. We are honored and fortunate to be working with such a talented group of advisors as we build the company,” noted CEO and co-founder, Gary D. Glick.
About IFM Therapeutics
IFM Therapeutics is a privately held biopharmaceutical company based in Cambridge, Massachusetts. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. In June of 2016, IFM closed a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. For more information, please visit www.ifmthera.com.
SVP of Business Development, Operations, and Strategy
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom